Are mAbs the ultimate targeted therapy?
Since the 1980’s, monoclonal antibodies (mAbs) have revolutionized healthcare and continue to do so. A short history of mAb approvals shows their increasing sophistication and targeting of disease...
The Bio-Blog
QuickTip #2: choosing IEX resin
Recovery of your biologically active target substance is a priority, and it’s important to check for its pH and ionic strength stability values...
CHO cells in fed-batch bioreactors dominate mAb upstream processes
Choosing a mammalian cell line or other type of host is as critical a question as any other in the complex world of monoclonal antibody (mAb) manufacture. We take a look at the present status, with...
QuickTip #1: cleaning IEX columns
When an IEX resin has been used for some time, impurities may build up in the column causing loss of resolution or increase in back pressure (shown on the pressure monitor or seen by gap formation on...
Illnesses with approved monoclonal antibody therapies
As our understanding of diseases at the molecular level increases, so does the potential for monoclonal antibody (mAb) - related therapies. Platform approaches to mAb production, including...
Improve peptide purification for affordable insulin
The global diabetes pandemic has created a massive demand for insulin, especially in China, which is expected to soon have half the world’s diabetes patients. Meeting this demand means developing...
How to improve process efficiency and economy in peptide production
The purity requirements for therapeutic peptides are very stringent, but synthesis generates a crude peptide mixture containing failed sequences and chemical variants, while recombinant peptides have...
mAb Purification – an overview of the essentials
Five of the top ten best selling drugs in 2017 were mAbs and the global mAbs market is expected to reach USD 219 billion by the end of 2023. The mAbs entering the clinic today are highly engineered...
The promise and the price of the new biopharmaceuticals
The healthcare sector and developers of new pharmaceuticals are facing increasing challenges, along with pressure to lower costs. At the same time pharmaceutical development is undergoing a...
Optimizing mAb purification with next generation protein A resin
The market for monoclonal antibodies (mAbs) is constantly growing as mAb therapies are generally considered to be both safe and effective treatments for difficult diseases like cancer and rheumatoid...